Catumaxomab
| Monoclonal antibody | |
|---|---|
| Type | Trifunctional antibody |
| Source | Rat/mouse hybrid |
| Target | EpCAM, CD3 |
| Clinical data | |
| Trade names | Removab, others |
| AHFS/Drugs.com | International Drug Names |
| Routes of administration | intraperitoneal infusion |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| (what is this?) (verify) | |
Catumaxomab, sold under the brand name Removab among others, is a rat-mouse hybrid monoclonal antibody which is used to treat malignant ascites, a condition occurring in people with metastasizing cancer. It binds to antigens CD3 and EpCAM. It was developed by Fresenius Biotech and Trion Pharma (Germany).